Literature DB >> 18854914

Cerebral tubercular lesions in a patient treated with infliximab for Crohn's disease.

V Galati, E Grilli, E Busi Rizzi, C Prantera, N Petrosillo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18854914     DOI： 10.1007/s00415-008-0042-4

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  9 in total

1.  [Pulmonary tuberculosis with cerebellar lesion in a patient after anti-TNF-alpha (infliximab) treatment for rheumatoid arthritis].

Authors:  Mikio Ubukata; Noboru Takayanagi; Tsutomu Yanagisawa; Yousuke Miyahara; Motoko Kubota; Kenichirou Hara; Hiroo Saitoh; Daidou Tokunaga; Kazuki Kurashima; Yutaka Sugita
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2005-04

2.  Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference.

Authors:  A Kornbluth
Journal:  Inflamm Bowel Dis       Date:  1998-11       Impact factor: 5.325

Review 3.  Infections in the immunocompromised rheumatologic patient.

Authors:  Stephen B Greenberg
Journal:  Crit Care Clin       Date:  2002-10       Impact factor: 3.598

4.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

Review 5.  New drugs for the treatment of rheumatoid arthritis.

Authors:  A A Schuna; C Megeff
Journal:  Am J Health Syst Pharm       Date:  2000-02-01       Impact factor: 2.637

Review 6.  BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment.

Authors: 
Journal:  Thorax       Date:  2005-07-29       Impact factor: 9.139

Review 7.  Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.

Authors:  Michael A Gardam; Edward C Keystone; Richard Menzies; Steven Manners; Emil Skamene; Richard Long; Donald C Vinh
Journal:  Lancet Infect Dis       Date:  2003-03       Impact factor: 25.071

8.  Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2004-08-06       Impact factor: 17.586

Review 9.  Biological therapies in the spondyloarthritides--the current state.

Authors:  J Braun; J Sieper
Journal:  Rheumatology (Oxford)       Date:  2004-06-08       Impact factor: 7.580
  9 in total
  1 in total

Review 1.  Central Nervous System Infections Associated with Immunosuppressive Therapy for Rheumatic Disease.

Authors:  Michael J Bradshaw; Tracey A Cho; Felicia C Chow
Journal:  Rheum Dis Clin North Am       Date:  2017-08-23       Impact factor: 2.670
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.